I think this is a very realistic view, it is nice to be
I think this is a very realistic view, it is nice to be optimistic but in reality what you describe is easier to believe. However, i think of cytodyn's situation in a way as the same feeling you get went looking at a mountain you must climb. at the base, looking up, it is an impossible looking task and the further you get, the more un- motivating it gets because the effort expands faster than the progress you make. When you get to the top, you look around and strangely all the thoughts you had of how impossible this climb is while doing it fade away and it seems like it always was an achievable task. It is just perspective.
There is nothing stopping a PR that cytodyn has a major partner in NASH. It is optimistic but there is no lack of data showing Leronlimab is doing what no other drug has done in phase 2.
Cytodyn may have already compiled the extra data from the mTNBC trial and we are deep into the 60 day review for BTD. Maybe we applied for a different cancer BTD using the basket trial?
The BLA may have already been sent tot he FDA and we might get the first knowledge of it when the FDA gives a PUFTA date.
Cytodyn is not just sitting around waiting fo rhte phone to ring. there are many VC firms that only watch biotechs like cytodyn and jump in because they know a BP is going to want leronlimab very badly very soon. BP knows about leronlimab and they know the FDA, they see the opportunity - just have not acted yet.
another clear thing is, Cytodyn is not selling this short. they know what the have and so do we. We have to just play to the audience when it benefits us. keep in mind, all the active employees and BOD have other careers and are already wealthy, they are not in a desperate situation. the "Nader's in it for the paycheck" is old now.
5
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A New Chapter for a Seasoned Leader When a high flyer like Stephanie Knepp steps into a new arena, you know folks are going to sit up and pay attention. This time, she's making waves by joining the Exceptional Women Alliance (EWA), a heavy-hitting community of women leaders. With her extensive background in scaling businesses and empowering leaders, she's bound to bring...
Continue Reading
Curaleaf's Determined Pursuit of Aurora Another day, another chess move in the cannabis world. Curaleaf is standing tall amid talk of a buyout, putting a foot forward to highlight its determination in the battle for Aurora. They've put forth an alternative to the proposal poised by Organigram, raising stakes and eyebrows alike. Aurora Cannabis is in the middle of a dance...
Continue Reading
Quick Detection for Deadly Viruses In the world of diagnostics, speed isn't just a luxury; it's a lifeline. Cepheid’s latest move—getting the FDA’s nod for their Xpert Hemorrhagic Fever Panel Test—is a big deal. Why? Imagine being able to detect nasty viruses like Ebola, Marburg, Lassa, and Crimean-Congo hemorrhagic fever in just over an hour. That's what this...
Continue Reading
Untapped Opportunities Between Africa and the Caribbean Who's ready to shake up the trade game between Africa and the Caribbean? According to a fresh-off-the-press report from the International Trade Centre (ITC) and Afreximbank, we could be looking at a whopping $1.65 billion in annual trade between these two regions by 2030. That's right, a billion with a 'B'. But let...
Continue Reading
Are Shareholder Interests Truly Represented? Let's dive into the murky waters stirred up by Halper Sadeh LLC's probe into three pivotal transactions involving Synaptics Incorporated (NASDAQ: SYNA), Capital Bancorp, Inc. (NASDAQ: CBNK), and SoundThinking, Inc. (NASDAQ: SSTI). Each of these deals has shareholders wondering if they're getting the short end of the stick while...
Continue Reading
OSL's New Move: Instant Redemption on the Table Alright, let's chew over OSL's latest gambit—you know, those folks (HKEX: 863) who are knee-deep in the digital currency swamp. They've launched this "Instant Redemption" feature for these fancy real-world asset products, and USDGO Plus SP is right there at the forefront. Getting the Fine Print Straight Now, not just...
Continue Reading
Shaky Ground Beneath AppLovin's Feet Ah, the sweet smell of litigation in the tech space—it’s like déjà vu for seasoned market folks. Here we have AppLovin, nestled comfortably in San Francisco, now eying a saucy class-action lawsuit. We're looking at shareholders taking a firm stance against some arguably misleading claims. We're talking big deals with allegations...
Continue Reading
A Steady March Forward for Yum China Yum China's third-quarter results reveal a company moving like a well-oiled machine, even in a turbulent market. A revenue uptick of 8% is no small feat, especially when operating under the weight of a 3% rise in system sales that neatly sidesteps the usual foreign exchange hiccups. This ain't just about keeping the lights on; it's...
Continue Reading
Setting the Stage at SEMA 2026 In the chaotic whirl of the 2026 SEMA Show, Massimo Group didn't just roll out new wheels—they took a leap into the big leagues. Amidst the bustling Vegas crowd, Massimo unveiled their latest babies: the Warrior 1500XD and the Sentinel 1500 HVAC Crew. These ain't just any UTVs; they're packing some serious muscle with a 1,499cc engine,...
Continue Reading
Chuck Prow Steps Into the CEO Role at APTIM It ain't every day that a seasoned veteran like Chuck Prow takes the helm at a company shaping the backbone of society. Yet here we are, seeing this gritty player onboard APTIM, a name synonymous with high-stakes environmental and resilience consulting. On November 9, with the baton officially passed from Mark Fallon, it's clear...
Continue Reading
Top 5 Most Recently Viewed Articles
Archer Aviation Marks a Significant Regulatory Milestone Archer Aviation Inc. (NYSE: ACHR) has taken a major step forward in the world of aviation with the early release of the Federal Aviation Administration's (FAA) final powered-lift Special Federal Aviation Regulation (SFAR). This regulation is pivotal as it lays a solid operational framework for the commercialization...
Continue Reading
Unicycive Therapeutics Faces Legal Challenges In a recent development, investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) are urged to secure legal counsel ahead of a critical deadline related to a securities fraud lawsuit. The legal notification indicates that those who purchased securities of the company between specific dates may have been misled regarding the...
Continue Reading
New Legislative Proposal on Dual Citizenship Melania Trump's former immigration lawyer has voiced strong criticisms against a recent legislative proposal aimed at abolishing dual citizenship in the U.S. This bill, introduced by Republican Sen. Bernie Moreno, is causing considerable debate regarding its potential implications for U.S. citizens, particularly for those who,...
Continue Reading
QuantumScape's Ambitious Plans for Solid-State Batteries QuantumScape Corp. (NYSE: QS) is making waves in the automotive industry with its groundbreaking technology in solid-state batteries. The CEO, Siva Sivaram, recently expressed optimism about the partnership with Volkswagen AG (OTC: VWAGY) which is set to revolutionize electric vehicle (EV) technology. Solid-State...
Continue Reading
Understanding the Unusual Options Activity of Riot Platforms Recently, significant activity has caught the attention of financial analysts looking at Riot Platforms. An in-depth analysis of the options history for Riot Platforms (NASDAQ: RIOT) has revealed an interesting trend consisting of 18 unusual trades that point toward strong market interest. In our investigation,...
Continue Reading